ReShape Lifesciences Inc
NASDAQ:RSLS
Intrinsic Value
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. [ Read More ]
The intrinsic value of one RSLS stock under the Base Case scenario is 1.3665 USD. Compared to the current market price of 0.1844 USD, ReShape Lifesciences Inc is Undervalued by 87%.
Valuation Backtest
ReShape Lifesciences Inc
Run backtest to discover the historical profit from buying and selling RSLS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of ReShape Lifesciences Inc's business.
What risks and challenges
does ReShape Lifesciences Inc face in the near future?
Summarize the latest earnings report
of ReShape Lifesciences Inc.
Provide P/E
for ReShape Lifesciences Inc and its competitors.
Balance Sheet Decomposition
ReShape Lifesciences Inc
Current Assets | 7.4m |
Cash & Short-Term Investments | 1.4m |
Receivables | 2.2m |
Other Current Assets | 3.8m |
Non-Current Assets | 400k |
PP&E | 300k |
Other Non-Current Assets | 100k |
Current Liabilities | 4.5m |
Accounts Payable | 1.5m |
Accrued Liabilities | 2m |
Other Current Liabilities | 1m |
Non-Current Liabilities | 200k |
Other Non-Current Liabilities | 200k |
Earnings Waterfall
ReShape Lifesciences Inc
Revenue
|
9.8m
USD
|
Cost of Revenue
|
-4.5m
USD
|
Gross Profit
|
5.3m
USD
|
Operating Expenses
|
-22.8m
USD
|
Operating Income
|
-17.5m
USD
|
Other Expenses
|
-8.8m
USD
|
Net Income
|
-26.3m
USD
|
Free Cash Flow Analysis
ReShape Lifesciences Inc
What is Free Cash Flow?
RSLS Profitability Score
Profitability Due Diligence
ReShape Lifesciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
ReShape Lifesciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
RSLS Solvency Score
Solvency Due Diligence
ReShape Lifesciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
ReShape Lifesciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RSLS Price Targets Summary
ReShape Lifesciences Inc
According to Wall Street analysts, the average 1-year price target for RSLS is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.
Ownership
RSLS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RSLS Price
ReShape Lifesciences Inc
Average Annual Return | -62.55% |
Standard Deviation of Annual Returns | 29.57% |
Max Drawdown | -100% |
Market Capitalization | 4.3m USD |
Shares Outstanding | 23 460 000 |
Percentage of Shares Shorted | 3.23% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The firm's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.
Contact
IPO
Employees
Officers
The intrinsic value of one RSLS stock under the Base Case scenario is 1.3665 USD.
Compared to the current market price of 0.1844 USD, ReShape Lifesciences Inc is Undervalued by 87%.